mugiwara
07/11/19 13:15
Ha respondido al tema Farmas USA
Ir a respuesta
TEVAResultados que son...meh...o bah...o pfff... https://ir.tevapharm.com/investors/press-releases/press-release-details/2019/Teva-Reports-Third-Quarter-2019-Financial-Results/default.aspx Revenues of $4.3 billionGAAP diluted loss per share of $0.29Non-GAAP diluted EPS of $0.58Free cash flow of $551 millionSpend base reduction of $2.9 billion since initiation of the restructuring plan in 2018; on-track to achieve $3.0 billion by the end of 2019Full year 2019 business outlook revised to:Net revenues of $17.2 - $ 17.4 billion (prior $17.0 - $ 17.4 billion )Operating income of $4.0 - $ 4.2 billion (prior $3.8 - $ 4.2 billion )EBITDA of $4.5 - $ 4.8 billion (prior $4.4 - $ 4.8 billion )EPS of $2.30 - $2.50 (prior $2.20 - $2.50 )Free cash flow of $1.7 - $2.0 billion (prior $1.6 - $2.0 billion )